HUTCHMED

We are happy to share that ELUNATE® (fruquintinib) has been enlisted in the Drug Formulary of the Hong Kong Hospital Authority (“HA”), categorized as a Special Drug. It is the first innovative oncology medicine ever to get enlisted in HA Drug Formulary directly under the Special Drug category. The enlistment is expected to take effect in mid-October 2024. https://lnkd.in/gdmTN3Dd

We are happy to share that our partner Takeda has received approval from the Japanese Ministry of Health, Labour and Welfare (MHLW)  for a new treatment for adults with previously treated metastatic colorectal cancer. Colorectal cancer is the most prevalent type of cancer in Japan, with an estimated 161,000 new cases and 54,000 deaths in 2023, according to the National Cancer Center’s statistics. https://lnkd.in/gjViNebK

We are happy to share that the results from savolitinib's Phase IIIb confirmatory study in treatment-naive NSCLC patients harbouring METex14 skipping mutations in China have been published in The Lancet Respiratory Medicine. The findings provide promising evidence for the use of savolitinib in the first-line setting in this population. https://lnkd.in/gZATUjpF

New and updated data from several studies of compounds discovered by HUTCHMED will be presented at the 2024 World Conference on Lung Cancer #WCLC2024 in San Diego, USA, and the European Society for Medical Oncology Congress 2024 #ESMO24, taking place in Barcelona, Spain. https://lnkd.in/gwdmYGMN

We will host a physician expert call with a professor and key opinion leader in immune thrombocytopenia (ITP), to discuss the treatment landscape of ITP via webcast on Wednesday, August 28, 2024, at 7:00 p.m. HKT. The event will be held in Chinese (Putonghua) and can be accessed via https://lnkd.in/gfhuPYFS The transcript of the event, including an English translation, will be available shortly thereafter for approximately 90 days. This event is intended for investor audiences only. ESLIM-01 is a Phase III trial of HUTCHMED’s novel investigational drug candidate sovleplenib in patients with primary ITP in China. The trial met all its endpoints and results were published in The Lancet Haematology and orally presented at the European Hematology Association (EHA) Hybrid Congress. HUTCHMED filed a New Drug Application in China in January 2024 for sovleplenib.

We are happy to share that we’ve established our new R&D center at the Hong Kong Science Park. Founded in 2000, HUTCHMED has emerged from a trailblazer in novel drug discovery, to a major player in China’s biotech industry.   We plan to focus on translational research and AI-driven drug discovery and the development of therapeutics for novel targets and diseases with high unmet medical needs at our Hong Kong R&D center. Leveraging HKSTP - Hong Kong Science and Technology Parks Corporation’s thriving biotech ecosystem comprising over 270 companies, HUTCHMED is set to drive groundbreaking pharmaceutical interventions.   A welcoming ceremony was hosted by HKSTP. Professor Sun Dong, Secretary for Innovation, Technology and Industry of the Hong Kong SAR government; Albert Wong, CEO of HKSTP; Gracie Ng, Chief of Staff of HKSTP; Dr Grace Lau, Head of Institute for Translational Research (ITR) of HKSTP; Dr Dan Eldar, Chairman of HUTCHMED; Dr Weiguo Su, CEO and CSO of HUTCHMED; Dr Michael Shi, Head of R&D and Chief Medical Officer of HUTCHMED and notable representatives and guests from both HKSTP and HUTCHMED attended the ceremony.   Professor Sun Dong, Secretary for Innovation, Technology and Industry said,” The Hong Kong Government’s commitment to enhancing Hong Kong’s R&D capabilities, particularly in the field of biotechnology, is unwavering. With our robust research capability, top-notch universities, advanced research facilities and increasingly vibrant ecosystem, Hong Kong is well-placed as one of the most desirable destinations to provide an integrated platform for biotech companies to innovate and translate their excellent R&D outcomes into clinical trials and commercialization. The agglomeration of more biotech companies like HUTCHMED in Hong Kong will create synergies to further strengthen our city’s advantage in life and health technology industry.”   Dr Weiguo Su, Chief Executive Officer and Chief Scientific Officer of HUTCHMED, said, “HUTCHMED has built a deep pipeline with multiple products approved in China and around the globe, with two of them also approved in Hong Kong. The establishment of the Research Centre in Hong Kong marks a new chapter for HUTCHMED. We believe it is an important step to accelerate and expand our global research and development activities. We are grateful for the support from the HKSAR government and the HKSTP, and look forward to working together in the future to bring more innovative therapies to patients worldwide.”   Albert Wong, CEO of HKSTP said,” It is a thrilling moment as we welcome HUTCHMED’s landing at Science Park. HKSTP’s extensive network connects our companies with a global array of thousands of investors and partners, accelerating the development and deployment of innovative therapies. With HUTCHMED's expertise and commercialization capabilities, the collaboration will provide invaluable insights to our local biotech firms and benefit the broader community.”

We're #hiring a new Associate Director, Medical Writing in Florham Park, New Jersey. Apply today or share this post with your network.

We are delighted to report our 2024 Interim Results and provide updates on key clinical and commercial developments. https://lnkd.in/g3QUN4Vf HUTCHMED has delivered strong performance in the first half of this year. Our team has made significant progress implementing our strategy in discovering and developing novel, effective medicines; conducting clinical trials in our home market and in the global markets; and rapidly advancing regulatory and commercial goals.

We will be announcing our 2024 interim results on Wednesday, July 31, 2024 at 7am Eastern Daylight Time (EDT) / 12 noon British Summer Time (BST) / 7pm Hong Kong Time (HKT). Analysts and investors are invited to join a conference call and audio webcast presentation with Q&A, conducted by HUTCHMED management. https://lnkd.in/gQNr5nvR

Since HUTCHMED began its sustainability journey in 2020, we have been integrating sustainability into every aspect of our business decisions and operations, strengthening our governance and endeavoring to align with the latest disclosure requirements, thereby striving to achieve industry best practice.   HUTCHMED scored 49 in the 2023 S&P Global ESG Ratings (90th percentile), significantly higher than the pharmaceutical industry average of 31 points. Mark Lee, Senior Vice President (Corporate Management and Communications) of HUTCHMED, was invited by S&P Global Market Intelligence to share insights on the topic "Unlocking the Potential of Sustainability Data" to more than 300 professionals from various industries around the world at its annual forum held in Hong Kong. Together with other panelists Francis Tong and Olivier Trecco, Mark shared how HUTCHMED has progressed and benefited from taking a more efficient and strategic-focused approach to ESG by upholding the importance of data granularity, including the full spectrum of Scope 3 data, within the Company. Please visit our website to learn more about HUTCHMED’s sustainability: https://lnkd.in/gY4X9aHU